laboratory informatics
PAREXEL LAUNCHES IDMP-FOCUSED SOFTWARE AND SERVICE SOLUTION
Parexel, a global biopharmaceutical services provider, has announced the launch of an Identification of Medicinal Products (IDMP)- focused solution for biopharmaceutical companies.
Liquent InSight for IDMP is the newest module added to Parexel’s Regulatory Information Management (RIM) platform. Beginning in 2018, the European Medicines Agency (EMA) will require biopharmaceutical companies to submit data on medicines in accordance with the International Organisation for Standardisation (ISO) IDMP standards.
Other major global market regulatory agencies are expected to follow suit. The standards are designed to increase transparency into authorised and investigational medicinal products to improve patient safety. Parexel’s Liquent InSight for IDMP allows biopharmaceutical companies to collect their data in a comprehensive and holistic manner. It is compliant with the five ISO IDMP standards defining product and registration data and details for investigational and registered medicinal products. In addition, Parexel Consulting’s subject matter experts work with clients to develop a comprehensive IDMP strategy that ensures globally standardised data.
‘As biopharmaceutical companies establish their IDMP programs, they will require capabilities to help them meet global standards and eliminate complexity,’ said Paul Bidez, PhD, vice president, regulatory solutions, Parexel. ‘Our solution combines deep subject matter expertise, specialised master data management, integration services, and purpose-built technology. With this new offering, Parexel clients gain a well-structured IDMP program with the potential to ensure compliance, provide greater efficiency, reduce costs, and simplify processes.’ Parexel’s end-to-end IDMP solution is available around the world, directly from Parexel or through the Parexel Partner Program. The solution can be deployed on-premises or in Parexel’s Regulatory Cloud, a life sciences content and regulatory information management solution structured within a dedicated, private cloud environment.
10 SCIENTIFIC COMPUTING WORLD
Optibrium and MolPort to improve speed and cost-efficiency of drug discovery
O
ptibrium, a developer of soſtware for small molecule design and optimisation, has announced a collaboration with MolPort, a
company that develops a comprehensive chemical database, marketplace and order fulfilment platform. Te collaboration offers StarDrop
users fully integrated access to MolPort’s drug discovery database of 6.3 million commercially available screening compounds and chemical building blocks via its curated collection of catalogues from major chemical suppliers. Te latest in a series of recent partnerships with commercial providers, this link with MolPort further extends StarDrop’s capabilities to improve the speed, efficiency, and productivity of the drug discovery process. MolPort specialises in the sourcing, and
effective single supplier access, of chemicals for drug discovery. From a collection of curated catalogues
from all major suppliers, MolPort has created a marketplace and order fulfilment platform for commercially available chemistries which includes 6.7 million high-
throughput screening (HTS) compounds. StarDrop users can access the MolPort
database to quickly search for commercially available screening compounds and reagents. Te free link enables users to not only look for exact chemical matches but also select compounds based on similarity to the chemistry of interest. Tis provides an invaluable tool for chemists to easily enrich their understanding of structure– activity relationships (SAR) in a project’s chemistry. MolPort’s compound search results are presented directly in StarDrop, where its capabilities for analysis of SAR and compound optimisation guide the selection of compounds with an improved chance of success. Dr Matthew Segall, CEO of Optibrium,
commented: ‘We are pleased to be working with MolPort in our latest collaboration with leading providers in drug discovery and wider chemistry fields. MolPort specialises in sourcing large numbers of chemicals from an array of large suppliers, and the more niche suppliers and StarDrop users can now benefit from seamless access to some 6.3 million screening compounds and building blocks.’
Autoscribe Informatics expansion ‘a sign of prosperous times’
Autoscribe Informatics, developer, and supplier of the Matrix Gemini Laboratory Information Management System (LIMS), has moved to larger premises in the UK. As from 21 November, the company’s headquarters are located in Aldermaston, near Reading in the UK. John Boother, president of Autoscribe
Informatics, said: ‘Tis expansion is the latest phase in a period of sustained investment into Autoscribe’s worldwide business. Over the last few years, this has included the purchase of our distributor in the USA to create a wholly-owned subsidiary there, the appointment of additional distributors throughout the world and the establishment of an office in the north of the UK to support our installations in that part of the country.’ Earlier this year, Autoscribe announced a record order intake for its laboratory
information management systems (LIMS) in the USA. Results for the six months to April 2016 showed a total increase of orders of 161 per cent, with April itself showing the highest ever order book for a single month. At that time Boother commented that while this success was related to the success of Autoscribe’s Matrix Gemini soſtware ‘it is still vitally important that our team works closely with customers to fully understand their current and future needs and ensure that systems we provide are exactly fit for purpose.’ Boother said: ‘Accompanying this
investment, we have seen continued and significant growth not only in the sales of our LIMS and Business Information Management Systems but also in our support business. We have therefore needed more people, and have now outgrown our old premises.’
@scwmagazine l
www.scientific-computing.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32
